Clinical Trial Update: Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sintilimab with chemoradiotherapy for locoregionally-advanced nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer
• Nasopharyngeal Neoplasms

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Neoplasms | Phase 3 | Status: UNKNOWN